VIRAGEN INC Form 8-K January 30, 2003

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

January 30, 2003

Date of Report (Date of earliest event reported)

VIRAGEN, INC.

(Exact name of registrant as specified in its charter)

(State or other jurisdiction of incorporation)

865 SW 78th Avenue, Suite 100, Plantation, Florida 33324 (Address of principal executive offices)

(P54) 233-8746 (Registrant s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Item 5. Other Events

On January 30, 2003, Viragen, Inc. announced that effective immediately Mr. Carl N. Singer will succeed Gerald Smith as Chairman of the Board of Directors and Mr. Robert C. Salisbury will succeed Mr. Smith as President and Chief Executive Officer. Mr. Smith will continue to serve on Viragen s Board of Directors.

A copy of the press release dated January 30, 2003 issued by the Company is filed as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7. Financial Statements and Exhibits

(c) Exhibits

99.1 Press Release dated January 30, 2003.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VIRAGEN, INC.

Date: January 30, 2003 By: /s/ Dennis W. Healey

Dennis W. Healey Executive Vice President and Chief Financial Officer

3

Index to Exhibits

Exhibit No.	Exhibit Title
99.1	Press Release dated January 30, 2003.